Atlas Trials

Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue

6 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue

RecordFirmDate
Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment (NCT07638722)SWOG Cancer Research Network2026-10-03
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT06859008)City of Hope Medical Center2025-08-25
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma (NCT04635683)Yazeed Sawalha2022-09-30
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma (NCT05169658)University of Washington2022-03-23
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma (NCT02339922)University of Washington2016-05-19
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas (NCT02332980)Mayo Clinic2015-02-19

Track Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue automatically

Every clearance here is in the API, with alerts when new ones post.